Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Leases (2021 - 2025)

Historic Current Leases for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.8 million.

  • Krystal Biotech's Current Leases rose 4552.18% to $1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 million, marking a year-over-year increase of 4552.18%. This contributed to the annual value of $1.8 million for FY2025, which is 4552.18% up from last year.
  • Latest data reveals that Krystal Biotech reported Current Leases of $1.8 million as of Q4 2025, which was up 4552.18% from $1.7 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Current Leases registered a high of $1.8 million during Q4 2025, and its lowest value of $648000.0 during Q1 2021.
  • Moreover, its 5-year median value for Current Leases was $1.4 million (2022), whereas its average is $1.4 million.
  • Per our database at Business Quant, Krystal Biotech's Current Leases surged by 11774.69% in 2022 and then tumbled by 1743.55% in 2024.
  • Krystal Biotech's Current Leases (Quarter) stood at $1.0 million in 2021, then skyrocketed by 49.95% to $1.6 million in 2022, then dropped by 5.57% to $1.5 million in 2023, then dropped by 17.44% to $1.2 million in 2024, then soared by 45.52% to $1.8 million in 2025.
  • Its Current Leases was $1.8 million in Q4 2025, compared to $1.7 million in Q3 2025 and $1.6 million in Q2 2025.